CYP17 and breast cancer risk: The polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2825-2828

  Kristensen, Vessela Nedelcheva ^a,d   Haraldsen, Ellen K ^a   Anderson, Kristin B ^a   Lonning P E ^b   Erikstein, Bjørn ^a   Kåresen, Rolf ^c   Gabrielsen, Odd S ^a   Børresen Dale, Anne Lise ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 ISOENZYME; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING;

EID: 0033564094     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Martucci, C. P., and Fishman, J. P450 enzymes of estrogen metabolism. Pharmacol. Ther., 57: 237-257, 1993.
2. Voutilainen, R., and Miller, W. L. Developmental expression of genes for steroidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 α-hydroxylase/17,20 lyase), and P450c21 (21-hydroxylase) in the human fetus. J. Clin. Endocrinol. Metab., 63: 1145-1150, 1986.
3. Thomas, H. V., Key, T. J., Allen, D. S., Moore, J. W., Dowsett, M., Fentiman, I. S., and Wang, D. Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br. J. Cancer, 75: 1075-1079, 1997.
4. Hankinson, S. E., Willett, W. C., Manson, J. E., Colditz, G. A., Hunter, D. J., Spiegelman, D., Barbieri, R. L., and Speizer, F. E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst., 90: 1292-1299, 1998.
5. Hiegelson, H. S., and Henderson, B. E. Estrogens and breast cancer. Carcinogenesis (Lond.), 17: 2279-2284, 1996.
6. Picardo-Leonard, J., and Miller, W. L. Cloning and sequence of the human gene for p450c 17 (steroid 17a-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA, 6: 439-448, 1987.
7. Carey, A. H., Chan, K. L., Short, F., White, D., Williamson, R., and Franks, S. Evidence for a single gene effect causing polycistic ovaries and male pattern baldness. Clin. Endocrinol., 38: 653-658, 1993.
8. Feigelson, H. S., Coetzee, G. A., Kolonel, L. N., Ross, R. K., and Henderson, B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 57: 1063-1065, 1997.
9. Feigelson, H. S., Shames, L. S., Pike, M. C., Coetzee, G. A., Stanczyk, F. Z., and Henderson, B. E. A cylochrome p450c17a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res., 58: 585-587, 1998.
10. Kadonada, J. T., Camer, K. R., Masiarz, F. R., and Tjan, R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell, 51: 1079-1090, 1987.
11. Gidoni, D., Dynan, W. S., and Tjan, R. Multiple specific contacts between a mammalian transcription factor and its cognate promoters. Nature (Lond.), 312:409-413, 1984.
12. Yu, C. Y., Motamed, K., Chen, J., Bailey, A. D., and Shen, S. K. J. The CACC box upstream of human embryonic ε-globin gene binds Sp1 and is a functional promoter element in vitro and in vivo. J. Biol. Chem., 14: 8907-8915, 1991.
13. Nedelcheva Kristensen, V., Andersen, T. I., Lindblom, A., Nesland, J., Olsen, A., and Børresen-Dale, A-L. A rare CYP19 (aromatase) variant increases the risk of breast cancer. Pharmacogenetics, 8: 43-48, 1998.
14. Bukholm, I. K., Nesland, J., Kåresen, R., Jacobsen, U., and Børresen-Dale, A-L. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J. Pathol., 181: 140-145, 1997.
15. Oelgeschlager, M., Nuchprayoon, I., Luscher, B., and Friedman, A. D. C/EBP, c-Myb and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol. Cell. Biol., 16: 4717-4725, 1996.
16. Dunning, A. M., Healey, C. S., Pharoah, P. D. P., Foster, N. A., Lipscombe, J. M., Redman, K. L., Easton, D. F., Day, N. E., and Ponder, B. A. J. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br. J. Cancer, 77: 2045-2047, 1998.
17. Weston, A., Pan, C-f., Bleiweiss, I. J., Ksieski, H. B., Roy, N., Maloney, N., and Wolf, M. S. CYP17 genotype and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 941-945, 1998.
18. Helzlsouer, K. J., Huang, H-Y., Strickland, P. T., Hoffman, S. H., Alberg, A. J., Comstock, G. W., and Bell, D. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol. Biomark. Prev., 7: 945-951, 1998.
19. Nakajin, S., Shinoda, M., Haniu, M., Shively, J. E., and Hall, P. F. C21 steroid side chain vleavage enzyme from porcine adrenal microsomes: purification and characterization of the 17a hydroxylase/C17,20-lyase cytochrome P450. J. Biol. Chem., 259: 3971-3976, 1984.
20. Santen, R. J., Samojlik, E., and Wells, S. A. Resistance of the ovary to blockade of aromatization with aminogluthimide. J. Clin. Endocrinol. Metab., 51: 473-477, 1980.